samedan logo
 
 
 
spacer
home > ebr > spring 2017 > editor’s letter
PUBLICATIONS
European Biopharmaceutical Review

Editor’s Letter

Proteins, proteins, proteins. They are a main feature in our spring edition of EBR – perhaps not surprisingly, considering the continued increase in adoption to clinical practice of high-value, high-performing protein therapeutics and the need for their manufacture at scale by the biopharmaceutical industry.

Rentschler Biotechnologie’s Dr Stefan R Schmidt and Dr Birgit Schwab would argue that, considering the market size and recent numbers of US and European approvals in these drug classes, the future for mid-size contract development and manufacturing organisations lies in complex proteins or ‘modern biopharmaceuticals’; monoclonal antibodies and proteins for cancer and autoimmune conditions in particular (see full pdf). In their articles, Christian Loch from AVMBioMed (see full pdf) and Kim Plasman, Kris Gevaert, Francis Impens and Tony Montoye (see full pdf) agree that, at present, proteomics is the best means for capturing this vital information.

AVMBioMed highlight the need to consider the importance of post-translational modification in defining the human protein repertoire, and the Trinean team plus Kris Gavaert and Francis Impens flag the need for further improvements in quality to move proteomics towards a unified regulatory process.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dr Deborah O’Neil, Chief Executive and Scientific Officer, NovaBiotics Ltd
spacer
Dr Deborah O’Neil
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

First own Gerresheimer Autoinjector - Gerresheimer and Midas Pharma announce strategic partnership

– Gerresheimer’s first own IP autoinjector suitable for both small and large molecules enhances broad portfolio of solutions, medical devices and pharmaceutical primary packaging – First joint project of Gerresheimer and Midas Pharma: Development and marketing of new autoinjector – One-stop-shop for biotech and pharma customers Duesseldorf, November 08, 2021 – Gerresheimer acquired the IP of a new generation cartridge based autoinjector from Midas Pharma. This is the start of a strategic partnership. The joint project comprises the development and marketing of the new generation autoinjector.
More info >>

White Papers
 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement